188 related articles for article (PubMed ID: 34975135)
1.
Panchal R; Bapat S; Mukherjee S; Chowdhary A
Indian J Pharmacol; 2021; 53(6):471-479. PubMed ID: 34975135
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Activity of Rosmarinic Acid Against Four Serotypes of Dengue Virus.
Panchal R; Ghosh S; Mehla R; Ramalingam J; Gairola S; Mukherjee S; Chowdhary A
Curr Microbiol; 2022 May; 79(7):203. PubMed ID: 35612625
[TBL] [Abstract][Full Text] [Related]
3. [Preparation and identification of neutralizing antibodies to envelope protein domain III(ED III) of the four dengue virus serotypes].
Ding X; Qiu L; Chen Y; Wen K
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Aug; 38(8):748-753. PubMed ID: 35851089
[TBL] [Abstract][Full Text] [Related]
4. Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication.
Abdul Ahmad SA; Palanisamy UD; Tejo BA; Chew MF; Tham HW; Syed Hassan S
Virol J; 2017 Nov; 14(1):229. PubMed ID: 29162124
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent Inhibitors for the Inhibition of Dengue Envelope Protein: An In Silico Approach.
Aarthy M; Singh SK
Curr Top Med Chem; 2018; 18(18):1585-1602. PubMed ID: 30360716
[TBL] [Abstract][Full Text] [Related]
6. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
8. Thioaptamers targeting dengue virus type-2 envelope protein domain III.
Gandham SH; Volk DE; Lokesh GL; Neerathilingam M; Gorenstein DG
Biochem Biophys Res Commun; 2014 Oct; 453(3):309-15. PubMed ID: 25261724
[TBL] [Abstract][Full Text] [Related]
9. A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection.
Panya A; Sawasdee N; Junking M; Srisawat C; Choowongkomon K; Yenchitsomanus PT
Chem Biol Drug Des; 2015 Nov; 86(5):1093-104. PubMed ID: 25891143
[TBL] [Abstract][Full Text] [Related]
10. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
11. Epitope prediction and designing of receptor inhibitor of Dengue Envelope Protein: An
Uttam G; Kumari A; Singh K
J Vector Borne Dis; 2023; 60(2):161-171. PubMed ID: 37417165
[TBL] [Abstract][Full Text] [Related]
12. Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes.
Hassandarvish P; Oo A; Jokar A; Zukiwski A; Proniuk S; Abu Bakar S; Zandi K
J Antimicrob Chemother; 2017 Sep; 72(9):2438-2442. PubMed ID: 28666323
[TBL] [Abstract][Full Text] [Related]
13. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
[TBL] [Abstract][Full Text] [Related]
14. Identification of sequence motifs involved in Dengue virus-host interactions.
Asnet Mary J; Paramasivan R; Shenbagarathai R
J Biomol Struct Dyn; 2016; 34(3):676-87. PubMed ID: 25905427
[TBL] [Abstract][Full Text] [Related]
15. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
16. Diterpenes/Diterpenoids and Their Derivatives as Potential Bioactive Leads against Dengue Virus: A Computational and Network Pharmacology Study.
Khan RA; Hossain R; Siyadatpanah A; Al-Khafaji K; Khalipha ABR; Dey D; Asha UH; Biswas P; Saikat ASM; Chenari HA; Wilairatana P; Islam MT
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833913
[TBL] [Abstract][Full Text] [Related]
17. Development of novel antiviral peptides against dengue serotypes 1-4.
Lee MF; Anasir MI; Poh CL
Virology; 2023 Mar; 580():10-27. PubMed ID: 36739680
[TBL] [Abstract][Full Text] [Related]
18. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach.
Galiano V; Garcia-Valtanen P; Micol V; Encinar JA
Drug Des Devel Ther; 2016; 10():3163-3181. PubMed ID: 27784988
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of therapeutic antibodies against dengue virus envelope protein receptor binding domain.
Chaudhuri D; Majumder S; Datta J; Giri K
Arch Microbiol; 2024 Jun; 206(7):312. PubMed ID: 38900285
[TBL] [Abstract][Full Text] [Related]
20. Targeting domain-III hinging of dengue envelope (DENV-2) protein by MD simulations, docking and free energy calculations.
Dubey KD; Tiwari G; Ojha RP
J Mol Model; 2017 Apr; 23(4):102. PubMed ID: 28255859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
